Richard Antoni Urbanowicz

List of Publications by Year
in descending order

48 papers	1,651 citations	331670 21 h-index	302126 39 g-index
54 all docs	54 docs citations	54 times ranked	2924 citing authors

#	Article	IF	Citations
1	An Antigenically Diverse, Representative Panel of Envelope Glycoproteins for Hepatitis C Virus Vaccine Development. Gastroenterology, 2022, 162, 562-574.	1.3	20
2	Inflammasome Contribution to the Activation of Th1, Th2, and Th17 Immune Responses. Frontiers in Microbiology, 2022, 13, 851835.	3.5	18
3	Immunogenicity of a new gorilla adenovirus vaccine candidate for COVID-19. Molecular Therapy, 2021, 29, 2412-2423.	8.2	41
4	The Distribution of Puumala orthohantavirus Genome Variants Correlates with the Regional Landscapes in the Trans-Kama Area of the Republic of Tatarstan. Pathogens, 2021, 10, 1169.	2.8	8
5	Two doses of the SARS-CoV-2 BNT162b2 vaccine enhance antibody responses to variants in individuals with prior SARS-CoV-2 infection. Science Translational Medicine, 2021, 13, eabj0847.	12.4	40
6	Challenges on the development of a pseudotyping assay for Zika glycoproteins. Journal of Medical Microbiology, 2021, 70, .	1.8	5
7	Long Term Immune Response Produced by the SputnikV Vaccine. International Journal of Molecular Sciences, 2021, 22, 11211.	4.1	9
8	Role of HVR1 sequence similarity in the cross-genotypic neutralization of HCV. Virology Journal, 2020, 17, 140.	3.4	3
9	A bivalent HCV peptide vaccine elicits pan-genotypic neutralizing antibodies in mice. Vaccine, 2020, 38, 6864-6867.	3.8	7
10	A next generation vaccine against human rabies based on a single dose of a chimpanzee adenovirus vector serotype C. PLoS Neglected Tropical Diseases, 2020, 14, e0008459.	3.0	18
11	Polymer microarrays rapidly identify competitive adsorbents of virus-like particles. Biointerphases, 2020, 15, 061005.	1.6	5
12	Adjuvant formulated virus-like particles expressing native-like forms of the Lassa virus envelope surface glycoprotein are immunogenic and induce antibodies with broadly neutralizing activity. Npj Vaccines, 2020, 5, 71.	6.0	21
13	Structure-Based Design of Hepatitis C Virus E2 Glycoprotein Improves Serum Binding and Cross-Neutralization. Journal of Virology, 2020, 94, .	3.4	17
14	Orthohantaviruses, Emerging Zoonotic Pathogens. Pathogens, 2020, 9, 775.	2.8	22
15	The Relationship of the Mechanisms of the Pathogenesis of Multiple Sclerosis and the Expression of Endogenous Retroviruses. Biology, 2020, 9, 464.	2.8	5
16	Hepatitis C Virus Vaccine: Challenges and Prospects. Vaccines, 2020, 8, 90.	4.4	53
17	Antigenicity and Immunogenicity of Differentially Glycosylated Hepatitis C Virus E2 Envelope Proteins Expressed in Mammalian and Insect Cells. Journal of Virology, 2019, 93, .	3.4	51
18	Cloning and Analysis of Authentic Patient-Derived HCV E1/E2 Glycoproteins. Methods in Molecular Biology, 2019, 1911, 275-294.	0.9	3

#	Article	IF	Citations
19	Standardized Method for the Study of Antibody Neutralization of HCV Pseudoparticles (HCVpp). Methods in Molecular Biology, 2019, 1911, 441-450.	0.9	17
20	InFusion Cloning for the Generation of Biologically Relevant HCV Chimeric Molecular Clones. Methods in Molecular Biology, 2019, 1911, 93-104.	0.9	1
21	Expression of human ficolin-2 in hepatocytes confers resistance to infection by diverse hepatotropic viruses. Journal of Medical Microbiology, 2019, 68, 642-648.	1.8	4
22	Immunization with a synthetic consensus hepatitis C virus E2 glycoprotein ectodomain elicits virus-neutralizing antibodies. Antiviral Research, 2018, 160, 25-37.	4.1	8
23	Enhanced nanoparticle uptake into virus infected cells: Could nanoparticles be useful in antiviral therapy?. International Journal of Pharmaceutics, 2018, 547, 572-581.	5.2	29
24	A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo. Antiviral Research, 2017, 148, 53-64.	4.1	18
25	An ancestral host defence peptide within human Î²-defensin 3 recapitulates the antibacterial and antiviral activity of the full-length molecule. Scientific Reports, 2016, 5, 18450.	3.3	35
26	Hepatitis C virus quasispecies and pseudotype analysis from acute infection to chronicity in HIV-1 co-infected individuals. Virology, 2016, 492, 213-224.	2.4	3
27	Human Adaptation of Ebola Virus during the West African Outbreak. Cell, 2016, 167, 1079-1087.e5.	28.9	180
28	A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance. Journal of Virology, 2016, 90, 3288-3301.	3.4	62
29	Novel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb. Journal of General Virology, 2016, 97, 82-94.	2.9	16
30	Flexible and rapid construction of viral chimeras applied to hepatitis C virus. Journal of General Virology, 2016, 97, 2187-2193.	2.9	11
31	Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay. Journal of General Virology, 2016, 97, 2265-2279.	2.9	33
32	Cholesterol conjugation potentiates the antiviral activity of an HIV immunoadhesin. Journal of Peptide Science, 2015, 21, 743-749.	1.4	5
33	Recombinant Human L-Ficolin Directly Neutralizes Hepatitis C Virus Entry. Journal of Innate Immunity, 2014, 6, 676-684.	3.8	28
34	Analysis of Serine Codon Conservation Reveals Diverse Phenotypic Constraints on Hepatitis C Virus Glycoprotein Evolution. Journal of Virology, 2014, 88, 667-678.	3.4	2
35	Dramatic Potentiation of the Antiviral Activity of HIV Antibodies by Cholesterol Conjugation. Journal of Biological Chemistry, 2014, 289, 35015-35028.	3.4	17
36	1178 A NANOBODY RECOGNIZING A NOVEL EPITOPE IN HEPATITIS C VIRUS GLYCOPROTEIN E2 BROADLY NEUTRALIZES VIRUS ENTRY AND INHIBITS CELLâ€“CELL TRANSMISSION. Journal of Hepatology, 2013, 58, S479.	3.7	0

#	Article	IF	Citations
37	An alpaca nanobody inhibits hepatitis C virus entry and cell-to-cell transmission. Hepatology, 2013, 58, 932-939.	7.3	69
38	Differential Activation of Killer Cells in the Circulation and the Lung: A Study of Current Smoking Status and Chronic Obstructive Pulmonary Disease (COPD). PLoS ONE, 2013, 8, e58556.	2.5	34
39	The Role of Humoral Innate Immunity in Hepatitis C Virus Infection. Viruses, 2012, 4, 1-27.	3.3	43
40	Naturally Occurring Antibodies That Recognize Linear Epitopes in the Amino Terminus of the Hepatitis C Virus E2 Protein Confer Noninterfering, Additive Neutralization. Journal of Virology, 2012, 86, 2739-2749.	3.4	54
41	The role of neutralizing antibodies in hepatitis C virus infection. Journal of General Virology, 2012, 93, 1-19.	2.9	58
42	Hepatitis C Patient-Derived Glycoproteins Exhibit Marked Differences in Susceptibility to Serum Neutralizing Antibodies: Genetic Subtype Defines Antigenic but Not Neutralization Serotype. Journal of Virology, 2011, 85, 4246-4257.	3.4	51
43	Quantitative Validation and Comparison of Multiplex Cytokine Kits. Journal of Biomolecular Screening, 2010, 15, 562-568.	2.6	90
44	Enhanced effector function of cytotoxic cells in the induced sputum of COPD patients. Respiratory Research, 2010, 11, 76.	3.6	52
45	Systems biology coupled with label-free high-throughput detection as a novel approach for diagnosis of chronic obstructive pulmonary disease. Respiratory Research, 2009, 10, 29.	3.6	21
46	Altered effector function of peripheral cytotoxic cells in COPD. Respiratory Research, 2009, 10, 53.	3.6	42
47	Killer cells in chronic obstructive pulmonary disease. Clinical Science, 2008, 114, 533-541.	4.3	37
48	EVALUATION OF FRESH AND CRYOPRESERVED HEPATOCYTES AS IN VITRO DRUG METABOLISM TOOLS FOR THE PREDICTION OF METABOLIC CLEARANCE. Drug Metabolism and Disposition, 2004, 32, 1247-1253.	3.3	264